US Tax Planning Mistakes Reducing Profits for Indian Pharma Companies - Indam Advisors
US tax planning errors can quietly drain profits for Indian pharmaceutical companies operating in the USA. Common gaps include improper entity structure, transfer pricing non-compliance, double taxation, and missed incentives. Strategic U.S. tax planning reduces risks, ensures IRS compliance, and improves operational profitability.
